Rhumbline Advisers Sutro Biopharma, Inc. Transaction History

Rhumbline Advisers

$104 Billion
Q1 2025

A detailed history of Rhumbline Advisers transactions in Sutro Biopharma, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 122,816 shares of STRO stock, worth $63,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares

122,816

Previous 126,698 3.06%

Holding current value

$63,864

Previous $233,000 61.37%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 08, 2025	SELL	$0.65 - $2.12 $2,523 - $8,229	-3,882 Reduced 3.06%	122,816 $90,000
Q4 2024 Jan 30, 2025	BUY	$1.82 - $4.4 $13,322 - $32,208	7,320 Added 6.13%	126,698 $233,000
Q3 2024 Nov 12, 2024	BUY	$2.88 - $5.01 $9,443 - $16,427	3,279 Added 2.82%	119,378 $413,000
Q2 2024 Aug 01, 2024	BUY	$2.92 - $5.33 $64,050 - $116,913	21,935 Added 23.29%	116,099 $340,000
Q1 2024 May 09, 2024	BUY	$3.27 - $5.65 $8,420 - $14,548	2,575 Added 2.81%	94,164 $532,000
Q4 2023 Feb 08, 2024	SELL	$2.07 - $4.54 $639 - $1,402	-309 Reduced 0.34%	91,589 $392,000
Q3 2023 Nov 09, 2023	BUY	$3.29 - $4.9 $7,402 - $11,025	2,250 Added 2.51%	91,898 $318,000
Q2 2023 Aug 08, 2023	BUY	$4.25 - $5.88 $21,046 - $29,117	4,952 Added 5.85%	89,648 $416,000
Q1 2023 May 11, 2023	BUY	$4.48 - $8.45 $31,024 - $58,516	6,925 Added 8.9%	84,696 $391,000
Q4 2022 Feb 14, 2023	BUY	$5.41 - $8.08 $36,717 - $54,838	6,787 Added 9.56%	77,771 $628,000
Q3 2022 Nov 10, 2022	BUY	$5.17 - $7.11 $42,538 - $58,501	8,228 Added 13.11%	70,984 $394,000
Q2 2022 Aug 11, 2022	BUY	$3.41 - $8.95 $25,847 - $67,841	7,580 Added 13.74%	62,756 $327,000
Q1 2022 May 12, 2022	SELL	$7.78 - $15.31 $6,200 - $12,202	-797 Reduced 1.42%	55,176 $454,000
Q4 2021 Feb 10, 2022	BUY	$14.25 - $23.53 $10,502 - $17,341	737 Added 1.33%	55,973 $833,000
Q3 2021 Nov 12, 2021	BUY	$16.88 - $22.38 $34,182 - $45,319	2,025 Added 3.81%	55,236 $1.04 Million
Q2 2021 Aug 05, 2021	BUY	$18.03 - $23.82 $431,998 - $570,727	23,960 Added 81.91%	53,211 $989,000
Q1 2021 May 06, 2021	BUY	$20.29 - $27.54 $31,246 - $42,411	1,540 Added 5.56%	29,251 $666,000
Q4 2020 Feb 10, 2021	BUY	$10.16 - $23.98 $73,162 - $172,679	7,201 Added 35.11%	27,711 $602,000
Q3 2020 Nov 12, 2020	BUY	$7.44 - $13.15 $12,923 - $22,841	1,737 Added 9.25%	20,510 $206,000
Q2 2020 Aug 13, 2020	BUY	$7.24 - $11.05 $36,019 - $54,973	4,975 Added 36.06%	18,773 $146,000
Q4 2019 Feb 05, 2020	BUY	$8.15 - $11.39 $1,793 - $2,505	220 Added 1.62%	13,798 $152,000
Q3 2019 Oct 23, 2019	BUY	$7.91 - $11.76 $9,143 - $13,594	1,156 Added 9.31%	13,578 $123,000
Q2 2019 Aug 14, 2019	BUY	$9.69 - $12.23 $120,369 - $151,921	12,422 New	12,422 $141,000

Others Institutions Holding STRO

# of Institutions

129

Shares Held

60.1M

Call Options Held

203K

Put Options Held

33.6K

View Full List

About SUTRO BIOPHARMA, INC.

Ticker STRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,161,500
Market Cap $27.1M
Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-dr...

More about STRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Sutro Biopharma, Inc. Transaction History